# Peachy Peptide reading list

> Peachy Peptide: selected publications — The Peachy Peptide reading list: KPV experiments, whole thymosin beta-4 studies and BPC-157 reviews relevant to the Wolverine pairing.

The human tolerability result, the preclinical experiments and the reviews relevant to this safety discussion.

## Human tolerability and molecular identity

The [healthy-volunteer trial](https://pubmed.ncbi.nlm.nih.gov/20536472/) tested whole thymosin beta-4. I would begin there, then turn to the [thymosin beta-4 review](https://pubmed.ncbi.nlm.nih.gov/22074294/) and the [actin-sequestration structural paper](https://pubmed.ncbi.nlm.nih.gov/15329672/) for the biological reason the smaller TB-500 fragment attracts interest. These publications answer different questions.

## KPV across experimental settings

The [intestinal-cell and mouse study](https://pubmed.ncbi.nlm.nih.gov/18061177/) and the [macrophage and mouse peritonitis study](https://pubmed.ncbi.nlm.nih.gov/12750433/) are useful companions because their inflammatory readouts differ. The [mouse recovery paper](https://pubmed.ncbi.nlm.nih.gov/18092346/) and the [rabbit corneal wound paper](https://pubmed.ncbi.nlm.nih.gov/16965771/) then move the discussion towards particular tissue outcomes. Nanoparticle and combination studies appear in the full list below.

## BPC-157 reviews

For Wolverine, the [systematic BPC-157 review](https://pubmed.ncbi.nlm.nih.gov/40756949/) and the [narrative BPC-157 review](https://pubmed.ncbi.nlm.nih.gov/40789979/) deserve a joint look. Their evidence counts differ, and neither provides a controlled combination study. The [review of peptide therapies in sports medicine](https://pubmed.ncbi.nlm.nih.gov/41966639/) supplies the broader safety context.

## References

[1] Zhang D, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combination treatment of acute and chronic DSS-induced colitis. Front Pharmacol. 2024;15:1442876. https://pubmed.ncbi.nlm.nih.gov/39211778/
[2] Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. https://pubmed.ncbi.nlm.nih.gov/28143741/
[3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[4] Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. https://pubmed.ncbi.nlm.nih.gov/18092346/
[5] Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. https://pubmed.ncbi.nlm.nih.gov/18612139/
[6] Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006;83(6):1366-1372. https://pubmed.ncbi.nlm.nih.gov/16965771/
[7] Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. https://pubmed.ncbi.nlm.nih.gov/12750433/
[8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[9] Morris DC, et al. A dose-response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 2014. https://pubmed.ncbi.nlm.nih.gov/25060418/
[10] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[11] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/
[12] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[13] et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[14] et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[15] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/

---

An independent repair-evidence digest that separates tissue signals from comfort and function outcomes; it is neither a clinic, a vendor, nor medical advice.